Hemab Therapeutics (COAG) vs Maze Therapeutics (MAZE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Hemab Therapeutics is the larger company by market cap ($1.44 billion vs $1.44 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COAG | MAZE |
|---|---|---|
| Share price | $30.89 | $25.88 |
| Market cap | $1.44B | $1.44B |
| 1-day change | +7.63% | -1.41% |
| YTD return | — | -36.64% |
| 1-year return | — | -5.78% |
| EPS (TTM) | $-4.33 | $-2.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $55.42 | $53.65 |
| 52-week low | $23.00 | $21.95 |
| Distance from 52-week high | -44.26% | -51.76% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +98.12% | +137.64% |
| Average volume | 453.97K | 560.26K |
| Shares outstanding | 46.71M | 55.55M |
| Employees | 59 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Hemab Therapeutics
COAG stock →Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 59 employees
About Maze Therapeutics
MAZE stock →Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 141 employees
COAG vs MAZE FAQ
Which is bigger, Hemab Therapeutics or Maze Therapeutics?
Hemab Therapeutics (COAG) is larger, with a market capitalization of $1.44B compared with $1.44B for Maze Therapeutics (MAZE).
Are Hemab Therapeutics and Maze Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.